RESUMO
BACKGROUND: Levetiracetam is the most commonly used antiepileptic drug in pregnant women due to its low teratogenic risk profile, favorable pharmacokinetic characteristics, and safety profile. Serum levels of levetiracetam vary in epilepsy during pregnancy. Therefore, the aim of the study was to evaluate the serum levels of levetiracetam during different trimesters of pregnancy by using therapeutic drug monitoring (TDM). MATERIALS AND METHODS: This was a single-center, prospective study. Pregnant women with epilepsy on levetiracetam were enrolled after getting written informed consent from them. Serum trough levels of levetiracetam were estimated at all trimesters by high-performance liquid chromatography (HPLC). RESULTS: The study included 16 participants with mean ± standard deviation (SD) age of 27.75 ± 4 years. There were nine (56.2%) participants with generalized seizure disorder and seven (43.8%) participants of focal seizure disorder. Among 16 patients, 10 (62.5%) participants were on levetiracetam alone and six (37.5%) participants were on levetiracetam combined with other antiepileptic drugs. In a total of 48 trough samples, 45 sample concentrations were below the therapeutic range of 12-46 mg/l and three sample concentrations were within the therapeutic range. There was a statistically significant difference in the concentration-dose ratio (CDR) of levetiracetam between the third and first trimesters (P-value 0.018). CONCLUSION: There was a statistically significant difference in serum levetiracetam concentration between the third and first trimesters. A well-conducted, intensive pharmacokinetic sampling study in PWWE with a control group is needed in future to evaluate the whole pharmacokinetic profile of levetiracetam and to correlate the clinical outcome.
Assuntos
Anticonvulsivantes , Monitoramento de Medicamentos , Epilepsia , Levetiracetam , Centros de Atenção Terciária , Humanos , Levetiracetam/farmacocinética , Levetiracetam/sangue , Levetiracetam/uso terapêutico , Feminino , Anticonvulsivantes/farmacocinética , Anticonvulsivantes/sangue , Anticonvulsivantes/uso terapêutico , Gravidez , Monitoramento de Medicamentos/métodos , Adulto , Epilepsia/tratamento farmacológico , Epilepsia/sangue , Estudos Prospectivos , Adulto Jovem , Trimestres da Gravidez/sangue , Complicações na Gravidez/tratamento farmacológico , Complicações na Gravidez/sangue , Piracetam/análogos & derivados , Piracetam/sangue , Piracetam/farmacocinética , Piracetam/uso terapêuticoRESUMO
AIMS: This multicenter prospective cohort study (registration no. ChiCTR2000032089) aimed to investigate the relationship between saliva and plasma levetiracetam concentrations to determine whether saliva could be used for routine monitoring of levetiracetam during pregnancy. METHODS: The slot concentrations of levetiracetam in simultaneously obtained saliva and plasma samples were measured using UPLC-MS/MS. The correlations between saliva and plasma levetiracetam concentrations and the dose-normalized concentrations were compared among pregnant women in different stages and nonpregnant control participants with epilepsy. RESULTS: In total, 231 patients with 407 plasma and saliva sample pairs were enrolled from 39 centers. Linear relationships between salivary and plasma levetiracetam concentrations were reported in the enrolled population (r = 0.898, p < 0.001), including pregnant (r = 0.935, p < 0.001) and nonpregnant participants (r = 0.882, p < 0.001). Plasma concentrations were moderately higher than saliva concentrations, with ratios of saliva to plasma concentrations of 0.98 for nonpregnant women, 0.98, 1, and 1.12 for pregnant women during the first trimester, the second trimester, the and third trimester, respectively. The effective range of saliva levetiracetam concentration was found to be 9.98 µg/mL (lower limit) with an area under the curve (AUC) of 0.937 (95% confidence intervals, 0.915-0.959), sensitivity of 88.9%, specificity of 86.8%, and p < 0.001, to 24.05 µg/mL (upper limit) with an AUC of 0.952 (0.914-0.99), sensitivity of 100%, specificity of 92.3%, and p = 0.007. CONCLUSION: The saliva/plasma concentration ratio of levetiracetam remains constant during pregnancy and is similar to that in non-pregnant individuals. Monitoring levetiracetam concentration in saliva during pregnancy should be widely promoted.
Assuntos
Anticonvulsivantes , Epilepsia , Levetiracetam , Saliva , Humanos , Levetiracetam/farmacocinética , Levetiracetam/sangue , Feminino , Saliva/química , Saliva/metabolismo , Gravidez , Anticonvulsivantes/farmacocinética , Anticonvulsivantes/sangue , Anticonvulsivantes/análise , Adulto , Epilepsia/tratamento farmacológico , Epilepsia/sangue , Adulto Jovem , Monitoramento de Medicamentos/métodos , Piracetam/análogos & derivados , Piracetam/análise , Piracetam/farmacocinética , Piracetam/sangue , Estudos Prospectivos , Estudos de Coortes , Espectrometria de Massas em Tandem/métodosRESUMO
Pese al creciente número de ensayos clínicos desarrollados para evaluar la cognición en el síndrome de Down, sus resultados para identificar intervenciones eficaces han sido muy limitados hasta la fecha. Las intervenciones en los modelos animales, con frecuencia muy favorables, no se han visto reflejadas en los ensayos clínicos. Esta revisión describe los resultados de los principales ensayos realizados. Ofrece consideraciones a los investigadores y describe estrategias a la industria farmacéutica para que se implique crecientemente en el descubrimiento de fármacos en el síndrome de Down
Although an increasing number of clinical trials have been developed for cognition in Down syndrome, there has been limited success to date in identifying effective interventions. This review describes the progression from pre-clinical studies with mouse models to human clinical trials research using pharmacological interventions to improve cognition and adaptive functioning in Down syndrome. We also provide considerations for investigators when conducting human clinical trials and describe strategies for the pharmaceutical industry to advance the field in drug discovery for Down syndrome
Assuntos
Humanos , Transtornos Cognitivos/tratamento farmacológico , Transtornos de Adaptação/tratamento farmacológico , Síndrome de Down/tratamento farmacológico , Cognição , Adaptação Psicológica , Rivastigmina/farmacocinética , Piracetam/farmacocinética , Memantina/farmacocinética , Drogas em InvestigaçãoRESUMO
Estudios recientes sugieren que la utilización de determinados psicofármacos, en combinación con terapia comportamental, puede ser de utilidad en la rehabilitación de las afasias, para acelerar la recuperación del lenguaje. En este artículo presentamos una revisión actualizada del tratamiento farmacológico de las afasias, centrada en las investigaciones con los compuestos sobre los que hay mayor evidencia clínica: bromocriptina, anfetaminas, donepezilo y piracetam
Recent studies suggest that the use of certain psychotropic drugs in combination with behavior therapy can be useful in the treatment of aphasia, accelerating language recuperation. We provide an update of pharmacological treatments for aphasia, focusing on the compounds for which there is greatest clinical evidence: bromocriptine, amphetamines, donepezil and piracetam